|
LIVE WEBINAR: Tuesday, April 20, 2021, 5:00 PM – 6:30 PM Eastern Time
Dissecting the Decision: Investigator Perspectives on Key Issues in the Management of Common Cancers13th Annual Oncology Grand Rounds NCPD Webinar SeriesNon-Small Cell Lung Cancer
Faculty
John V Heymach, MD, PhD Professor and Chair Thoracic/Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center Houston, Texas Paul K Paik, MD Associate Attending Physician Clinical Director, Thoracic Oncology Service Memorial Sloan Kettering Cancer Center New York, New York Zofia Piotrowska, MD, MHS Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital Boston, Massachusetts Nurse Case Presentations By
Kelly EH Goodwin, MSN, RN, ANP-BC Thoracic Cancer Center Massachusetts General Hospital Boston, Massachusetts Tara Plues, APRN, MSN Hematology and Medical Oncology Cleveland Clinic Cleveland, Ohio Victoria Sherry, DNP, CRNP, AOCNP Oncology Nurse Practitioner for Thoracic Malignancies Abramson Cancer Center Perelman Center for Advanced Medicine University of Pennsylvania Medical Center Faculty, University of Pennsylvania School of Nursing Philadelphia, Pennsylvania Moderator Neil Love, MD Research To Practice Miami, Florida Tuesday, April 20, 2021 Topics to Be Discussed
Target Audience
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. Credit Designation Statements This educational activity for 1.5 contact hours is provided by RTP. This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours. To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity. Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2021/NSCLC/ILNA Unlabeled/Unapproved Uses Notice There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified. Content Validation and Disclosures RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Heymach – Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, BrightPath Biotherapeutics Co Ltd, Bristol-Myers Squibb Company, Catalyst Pharmaceuticals, EMD Serono Inc, Foundation Medicine, Genentech, a member of the Roche Group, GlaxoSmithKline, Guardant Health, Hengrui Therapeutics Inc, Janssen Biotech Inc, Kairos Venture Investments LLC, Leads Biolabs, Lilly, Mirati Therapeutics, Nexus Health Systems, Novartis, Pneuma Respiratory, Roche Laboratories Inc, Sanofi Genzyme, Spectrum Pharmaceuticals Inc, Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Spectrum Pharmaceuticals Inc; Licensing and Fees: Spectrum Pharmaceuticals Inc. Dr Paik – Advisory Committee: Calithera Biosciences, EMD Serono Inc, Xencor; Consulting Agreements: Bicara Therapeutics, a wholly owned subsidiary of Biocon, Boehringer Ingelheim Pharmaceuticals Inc, GlaxoSmithKline; Contracted Research: EMD Serono Inc; Data and Safety Monitoring Board/Committee: Takeda Oncology. Dr Piotrowska – Advisory Committee: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, C4 Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medtronic Inc, Takeda Oncology; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Cullinan Oncology, Daiichi Sankyo Inc, Janssen Biotech Inc, Novartis, Spectrum Pharmaceuticals Inc, Takeda Oncology, Tesaro, A GSK Company. CONTRIBUTING NURSES — Ms Goodwin and Ms Plues had no relevant conflicts of interest to disclose. The following nurse practitioner reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Ms Sherry — Advisory Committee and Consulting Agreement: AstraZeneca Pharmaceuticals LP. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc. RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Merck, Regeneron Pharmaceuticals Inc and Sanofi Genzyme, and Takeda Oncology. |